Clinical Competition Candidate
ACUVUE THERAVISION WITH KETOTIFEN
ACUVUE THERAVISION WITH KETOTIFEN carries product patent, low complexity (0/5), and meaningful clinical competition (5/5). The listed expiry window is approximately 48 months away. Active clinical competition may compress the generic entry window.
LOE window
48months
to latest listed patent expiry (June 27, 2030)
Expiry attractiveness: 4/5
Patent profile
Substance patent (none)
Product / formulation patent (listed)
Use-code patent (none)
Patent count: 2
Complexity score: 0/5
Clinical competition
Score: 5/5
Active trials linked: 42
Phase 2/3 trials: 32
Higher scores indicate more trial activity for this ingredient — a proxy for competitive generic interest.
Drug overview
Active ingredient: KETOTIFEN FUMARATE
Applicant (NDA holder): JOHNSON AND JOHNSON VISION CARE INC
Confidence: High